Bios Pharmaceuticals

Bios Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing innovative products for the ophthalmic market. The company's lead product candidate, BIOS-01, is a proprietary subconjunctival injection intended for use during cataract surgery. BIOS-01 consists of a fixed-dose combination of triamcinolone acetonide, a corticosteroid, and moxifloxacin, an antibiotic. This "dropless" approach is designed to replace the standard post-operative regimen of multiple daily eye drops, which often suffers from poor patient compliance. By administering the medication directly at the surgical site, Bios Pharmaceuticals aims to ensure consistent drug delivery and improve clinical outcomes. The company is headquartered in Somerville, New Jersey, and continues to advance its clinical programs to address unmet needs in surgical eye care.